Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.
Naresh BummaBinod DhakalRaphael FraserNoel Estrada-MerlyKenneth AndersonCésar O FreytesGerhard C HildebrandtLeona HolmbergMaxwell M KremCindy LeeLazaros LekakisHillard M LazarusHira S MianHemant S MurthySunita NathanTaiga NishihoriRicardo D ParrondoSagar S PatelMelhem SolhChristopher StrouseDavid H VesoleShaji K KumarMuzaffar H QazilbashNina ShahAnita D SouzaSurbhi SidanaPublished in: Cancer (2023)
No superior outcomes were observed in patients with HRMM who received bortezomib monotherapy or (to a lesser extent) in those who received bortezomib in combination as maintenance compared with lenalidomide alone. Until prospective data from randomized clinical trials are available, post-transplant therapy should be tailored to each patient with consideration for treating patients in clinical trials that target novel therapeutic strategies for HRMM, and lenalidomide should remain a cornerstone of treatment.
Keyphrases
- cell therapy
- multiple myeloma
- newly diagnosed
- clinical trial
- end stage renal disease
- ejection fraction
- combination therapy
- chronic kidney disease
- prognostic factors
- open label
- electronic health record
- machine learning
- peritoneal dialysis
- randomized controlled trial
- low dose
- deep learning
- high dose
- glycemic control
- chronic lymphocytic leukemia
- phase ii
- patient reported